Method of treating chronic opisthorchiasis in patients with rosacea

FIELD: medicine.

SUBSTANCE: method involves administering an anthelminthic agent in the period of stationary process stage; the anthelminthic treatment is preceded by administering chophytol 200 mg 3 times a day before meals for 14 days; the anthelminthic treatment involves administering Osinol food supplement 2 tablets 3 times a day during meals for 14 days; thereafter, chophytol is taken in a dose of 200 mg 3 times a day before meals for 14 days; 7 days later, the repeated course of the anthelminthic treatment with Osinol food supplement 2 tablets 3 times a day during meals is prescribed to be administered for 14 days; the entire therapeutic course involves washing the face with the Setaphyldermocontrol foaming facial cleanser 2 times a day followed by applying an SPF30 product on the face once after the morning wash.

EFFECT: reducing the number of complications and the high efficacy of the anthelminthic treatment.

1 ex

 

The invention relates to medicine, dermatology and can be used for the treatment of chronic opisthorchiasis in patients with rosacea.

The closest to the proposed is a method for the treatment of patients with combined pathology with praziquantel, which is prescribed in the usual dose 60 mg/kg of body weight over night scheme in 3 divided doses every 4 hours [Beloborodova E. I.; N. To. Bychkova. Chronic opisthorchiasis. A modern view of the treatment"]. The effectiveness of deworming was 100%. However, for patients with rosacea this treatment causes a complication process of the skin in the form of appearance of new lesions, especially in the first days after deworming, accompanied by itching, burning and redness that requested additional detoxification isotonic sodium chloride solution for 5 days.

A new technical result - the reduction of complications in high-efficiency deworming.

To achieve the technical result in the method of treatment of chronic opisthorchiasis in patients with rosacea adopting funds for deworming in the period of the stationary stage of the process, before deworming administered hofitol 200 mg 3 times a day before meals for 14 days, and fish is carried out biologically active additive to food "Ocenol" 2 table�tki 3 times a day with meals for 14 days, then enter hofitol 200 mg 3 times a day before meals for 14 days, then 7 days, a second course of deworming biologically active additive to food "Ocenol" 2 tablets 3 times daily with food for 14 days, during the entire course of treatment for cleansing, use a foam "Setfilepointer" 2 times a day followed by application on the skin means SPF30 1 time after the morning wash.

The method is as follows.

The patient undergoes a physical examination (General blood test, General urine analysis, biochemical analysis of blood), liver ultrasound, fecal, duodenal intubation or enzyme-linked immunosorbent assay for opisthorchiasis to IgG. While in the duodenal bile eggs opistorhisov or increase the titer by ELISA in a patient with rosacea outpatient treatment. At the first stage before the treatment for stabilizing the patient with rosacea conduct detoxication therapy (a solution of sodium thiosulfate 30% 10 ml/No. 10), antihistamines (claritin 1 tablet 1 time a day for 10 days), sedatives (Afobazol 1 tablet 2 times a day for 20 days). Externally: zinc ointment 2% 2 times a day, facial wash "Setfilepointer" 2 times a day and moisturizer for face SPF30 - 1 once daily in the morning after cleansing foam or in 40-60 min�Les for application of 2% zinc ointment.

Later in the period the stationary stage of the process before deworming administered hofitol 200 mg 3 times a day before meals for 14 days, and fish is carried out biologically active additive to food "Ocenol" 2 tablets 3 times daily with meals for 14 days, then administered hofitol 200 mg 3 times a day before meals for 14 days, then 7 days, a second course of deworming biologically active additive to food "Ocenol" 2 tablets 3 times daily with food for 14 days during the entire course of treatment for cleansing, use a foam "Setfilepointer" 2 times a day followed by application on the skin means SPF30 1 time after the morning wash.

"Setfilepointer" (Cetaphil® Dermacontrol™) is a professional line of care for problem skin, prone to acne. Clinically proven that the use of Cetaphil® Dermacontrol™ in the treatment of acne provides: a significant reduction of side effects the treatment of acne (redness, dryness, peeling), intense and long lasting hydration of the skin within 24 h, gentle cleansing (without damaging the integrity of the skin barrier), protection from UV-A and UV-B radiation. In a cosmetic line Cetaphil® Dermacontrol™ includes: moisturizer for face SPF SPF30, 118 ml foam cleanser with physiological pH~5.1, 236 ml, �possession of ceramide and zinc. Cetaphil® Dermacontrol™ is used as a daily care for skin prone to acne, in the initial phase of treating acne when the skin adapts to the treatment, maintenance phase of treatment throughout the course of therapy. Method of application line Cetaphil® Dermacontrol™ facial cleansing foam 2 times a day (morning and evening) and moisturizer for face SPF30 - 1 per day in the morning after washing foam.

Product: moisturizer for face SPF SPF30 - 118 ml bottle, foam cleanser - dispenser bottle 236 ml.

The name and address of the manufacturer: Laboratoires Galderma, France, Zone Industrielle Montdesir, 74540 Albysur Cheran, France. Lab Galderma, France, Areas Industrial, Mondesir, 74540 Albisu Cheran, France.

Due to the increased sensitivity of the skin of the face in rosacea Soaps, alkaline and acidic cleansers perfumed undesirable. Cetaphil® Dermacontrol™ - foam cleanser with physiological pH~5.1, with the content of ceramide and zinc suitable for daily use and does not irritate the skin of patients with rosacea.

The new property of the drug was detected during the conduct of clinical trials in the treatment of patients with rosacea. We observed 10 patients. In patients with rosacea is marked dryness and peeling of the skin, due to the particularities of the skin in rosacea treatment (use 2% zinc ointment). One of the provoking and etiological factors in rosacea is the solar radiation, so patients with rosacea it is recommended to use sunscreen regardless of the time of year [Mihneva E. N. Treatment rosacea // Dermatology and venereology. - 2012. - №. 4. (58)]. Use moisturizer for the face "Cetaphil® Dermacontrol" SPF30 - 1 once daily in the morning after cleansing foam provides good moisture and protection from UV-A and UV-B rays.

Biologically active food Supplement "Ocenol" is a plant complex, consisting of aspen bark extract, Kuril tea extract, elecampane root, tansy, dandelion root, Senna leaf. Auxiliary components: crystalline glucose.

Aspen bark extract provides anti opisthorchosis, anti-inflammatory, choleretic action. Tansy exhibits antiparasitic activity against round and flat worms, has antispasmodic action; elecampane root anthelmintic action has disinfectant, diuretic and choleretic effect; dandelion root stimulates the appetite, helps dissolve gallstones. Kuril tea is used as an antispasmodic, analgesic, choleretic, antimicrobial agent. The most effectively removes the dysbacteriosis, dysbiosis. Senna leaf PR�changes as a mild laxative, promotes the excretion of parasites and their decay products.

Properties of bas "Ocenol": anthelmintic, anti-inflammatory, antimicrobial, antitoxic, antispasmodic, immunomodulatory, tonic, improves the appetite.

Method of application: adults and children over 14 years: take 2-3 tablets 3 times daily with meals, for greatest effectiveness, the drug can be taken 15-20 minutes before meals, with water (100-200 ml). The course of 2 weeks, then a break for 10-15 days, then taking 2 weeks. Prophylactic administration 15 days 2-3 times a year. In the case of some helminth infections (Giardia, opisthorchiasis, toxocariasis) the drug is intended for family use. Contraindications: individual intolerance of components, pregnancy, breast-feeding, caution is in cholelithiasis.

Product form: softgel weight 0,19.

Manufacturer: OOO "NPP Raduga", Nicaea Irina Yaroslavna, Novosibirsk, TU 9197-003-0136597351-07, Number and date of issue of the certificate: 77.99.23.3.At.229.1.07 dated 16.01.2007.

This food additive of plant origin, which is beneficial for the treatment of opisthorchiasis in patients with rosacea. Treatment of opisthorchiasis is performed after decrease in acute process so as not to cause complications with your skin process. Dose 2 tablets 3 times a day and the last�the sequence of the drug selected on the basis of clinical observations. After the course of treatment were duodenal intubation, according to which determined the effectiveness of deworming. The course of 14 days of biologically active food supplements "Ocenol" necessary and sufficient, which is confirmed by clinical observations, for this category of patients. When conducting deworming during the period of less than 14 days reduced the effectiveness of deworming and elongation of more than 14 days leads to additional side effects, undesirable for patients with rosacea. In the daytime the drug is given for the convenience of care for patients, in 2 divided doses to increase the concentration of herbal medicines to more effectively carry out deworming. The dose is 2 capsules 3 times a day for 14 days is necessary and sufficient for the clinical observations for an effective deworming in this category of patients. Appointment before deworming of hofitol, its choleretic and anti-inflammatory effects, allows to stop the inflammatory process in the biliary tract and to conduct deworming in more favorable conditions. The use of hofitol, possessing hepatoprotective choleretic action, reinforces a positive effect on the state of the biliary system, as� by this time relieved by the signs of acute inflammatory process in the biliary tract, but hypotension persists gallbladder.

Example

Patient T., age 51, went to a Regional hospital in the city of Tomsk with a diagnosis of Chronic opisthorchiasis. Chronic acalculous cholecystitis in a stage of moderate exacerbation. Biliary dyskinesia hypokinetic type. Related diagnosis: Rosacea, II subtype, papulopustules.

Upon receipt complained of heaviness in the right hypochondrium, a constant bitter taste in the mouth, nausea, decreased appetite, anxiety, flatulence, constipation.

From history revealed that the patient is sick rosacea for about 4 years. Last aggravation appeared 2 months ago. Communicates with nervous shock. At the first stage of the treatment to relieve acute: detoxification therapy (a solution of sodium thiosulfate 30% 10 ml/No. 10), antihistamines (claritin 1 tablet 1 time a day for 10 days), vitamin therapy ("Centrum" 1 capsule 1 time a day for 30 days), sedatives (Afobazol 1 tablet 3 times a day for 20 days). Externally: zinc ointment 2% 2 times a day, facial wash "Setfilepointer" 2 times a day and moisturizer for face SPF30 1 time per day in the morning after cleansing foam or 40 minutes - 1 hour after application of 2% zinc ointment.

The last 3 years began to disturb heaviness in the right hypochondrium, periodic painful�spine in this area, intolerance to fatty foods, nausea, anxiety.

Out-patient physical examination, ultrasound, duodenal intubation, ELISA opisthorchiasis to IgG.

In General, the analysis of blood eosinophilia of up to 8%. In General, the analysis of urine without pathological changes. Indicators of biochemical studies of blood in the normal range.

According to chromatic duodenal identified dyskinesia of the gallbladder hypokinetic type: gallbladder bile was due to expire in large volume to 109 ml (at a rate of 60 ml), time to expiration was extended to 43 minutes (at a rate of up to 21 min). Revealed hypotension sphincter of Oddi.

Microscopy bile found eggs opistorhisov (up to 6 in field of view). Increased titer by ELISA opisthorchiasis to IgG 0,59 (at a rate of 0.29).

According to the ultrasound of the gallbladder volume was significantly increased and amounted to 82 cm3 (at a rate of 40-60 cm3).

When it subsided the skin process the patient the treatment of chronic opisthorchiasis.

Objective: asthenic physique. On the face centrofacial (forehead, nose, cheeks, chin), which is the erythema with indistinct borders. On the background of erythema are small pink papules, elastic consistency. Is peeling in the nasolabial folds. On the skin of the chin are visible isolated pustules with pus. Skin shiny, then� extended.

Tongue coated with white bloom. The lungs and heart without pathology. The abdomen is soft, palpation in the right hypochondrium moderately painful. Positive symptoms of Kerala and Murphy.

For the treatment of chronic opisthorchiasis in the background of rosacea was followed by a second stage treatment according to the invention, carried out preparations for deworming hofitol 200 g 3 times a day before meals for 14 days, then deworming biologically active additive to food "Ocenol" 2 tablets 3 times daily with food for 14 days, after which patients received hofitol 1 tablet 3 times a day before meals for 14 days. Then after 7 days treatment with biologically active additive to food "Ocenol" 2 tablets 3 times daily with meals for 14 days repeated. Externally: zinc ointment 2% 2 times a day, facial wash "Setfilepointer" 2 times a day and moisturizer for face SPF30 1 time per day in the morning after cleansing foam or 40 minutes - 1 hour after application of 2% zinc ointment.

Treatment the patient underwent right. After deworming biologically active additive to food "Ocenol" side effects were noted. The appearance of lesions on the skin, itching was observed. On day 7 the use of "Ocenol" gone feeling of heaviness in the right hypochondrium, bitter taste in the mouth, by the end of treatment was nausea has improved APPA�it normalized stool. After treatment of chronic opisthorchiasis control were conducted duodenal intubation, ultrasound. According to fractional duodenal gallbladder bile volume, and time the expiry time is normalized to 65 ml (at a rate of 60 ml) and 26 min (at a rate of 21 min). When bile microscopy revealed individual eggs opistorhisov. According to the ultrasound of the gallbladder volume was 57 cm3, which is the norm. During the week after treatment was achieved regression of the manifestations of rosacea. A month after the treatment, the patient noted improvement of health, the complaints of the digestive tract did not show disappeared nausea, appetite returned to normal. Repeated duodenal intubation. Microscopic examination of eggs opistorhisov been identified. Skin process regressed, noted mild erythema of the cheeks.

In this way deworming took place 10 patients with rosacea in combination with chronic opisthorchosis. Side effects of the skin, gastrointestinal tract in the treatment of this method was observed. The effectiveness of deworming was 65.7 per cent.

Thus, the proposed method allows to treat patients with comorbidity using biologically active food supplements "Ocenol", derived from vegetable raw materials, combined�and application in the period of treatment care for face: make-up removers "Cetaphil® Dermacontrol™ and moisturizers for the face SPF30. The proposed method gave the possibility not to use highly toxic drug praziquantel and more gently with a sufficiently high efficiency (65,7%) to treat chronic opisthorchiasis in patients with rosacea.

A method for the treatment of chronic opisthorchiasis in patients with rosacea adopting funds for deworming in the period of the stationary stage of the process, characterized in that before deworming administered hofitol 200 mg 3 times a day before meals for 14 days, and fish is carried out biologically active additive to food "Ocenol" 2 tablets 3 times daily with meals for 14 days, then take hofitol 200 mg 3 times a day before meals for 14 days, next 7 days is prescribed a second course of deworming biologically active additive to food "Ocenol" 2 tablets 3 times daily with meals for 14 days, during the entire course of treatment for cleansing, use a foam "Setfilepointer" 2 times a day followed by application on the skin means SPF30 1 time after the morning wash.



 

Same patents:

FIELD: medicine.

SUBSTANCE: praziquantel is administered in a single dose of 20 mc/kg for the first day of treatment in the daytime, and withdrawn; on the following day, the conducted therapy is added with introducing Gelmicide, a biologically active food supplement, in a dose of 2 capsules with meals for 21 days; the course is repeated 10 days later in a dose of 2 capsules 2 times a day with meals for 14 days.

EFFECT: reducing the rate of complications and increasing the high dishelminthisation efficacy.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutics, namely, deals with compounds of formula , suitable for reduction of regulation of biological activity of melanocortin-5 receptor (MC5R). Such diseases and/or conditions include, but are not limited by, acne, seborrhoea, seborrheic dermatitis, cancer and inflammatory diseases.

EFFECT: compounds of claimed invention can be applied for treatment of diseases and/or conditions, in which reducing regulation of MC5R is favourable.

3 cl, 109 ex, 7 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula (I) : or a salt thereof, wherein R1 and R5 are independently selected from H, OH and alkoxy; R2-R4 and R6-R8 are independently selected from H, OH, F, Cl, Br and I; R9 and R10 are C2-C8 alkenyl; under the condition that at least one of R1, R5 and R7 is OH or alkoxy; at least one of R2-R4, R6 and R8 is F, Cl, Br or I; and R2 and R6 are Cl. The invention also relates to an antibacterial composition and treatment methods.

EFFECT: improved properties.

18 cl, 7 ex, 10 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, and represents a pharmaceutical composition in the form of gel, which contains clindamycin phosphate, a combination of gel-forming polymer and hydrophilic dispersion phase, pH control agent, allantoin and lauryliminodipropionate sodium tocopheryl phosphate; the ingredients of the composition are taken in certain ratio, in g per 100 g.

EFFECT: invention provides the high level of antibacterial activity and stability.

5 cl, 1 tbl

FIELD: medicine.

SUBSTANCE: present group of inventions refers to medicine, namely to dermatology, and concerns treating telangiectasia or related symptoms. To this effect, an involved skin area is coated with a composition containing from approximately 0.4 wt % to approximately 0.6 wt % brimonidine providing its blood serum or plasma concentration, Cmax of approximately 54±28 pg/ml or less and AUC0-24h of approximately 568±277 pg·h/ml or less.

EFFECT: method provides the effective treatment of telangiectasia or related symptoms with no side local and systemic effects.

20 cl, 6 dwg, 6 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry and represents a composition for treating acne, rosacea and hyperpigmentation, in the form of a gel which contains anchoic acid, a hydrophobic ingredient, a non-aqueous solvent, an emulsifying agent, a gel-forming polymer, a preserving agent, a pH control agent and additionally methylpyrrolidone with anchoic acid having a particle size of less than 100 mcm, while anchoic acid is related to methylpyrrolidone as 1:0.025 to 1:4.

EFFECT: invention provides easy penetration of anchoic acid through a horny layer and its resolution into the oil grand ducts and between skin cells, providing high concentration of anchoic acid that promotes better antibacterial, keratolytic and de-pigmentation effects.

5 cl, 2 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to a compound of Formula

,

where Y represents a group of formula -(CR9R10)-; X is selected from the group, consisting of -C(=O)-, -OC(=O)-, -NHC(=O)-, -(CR11R12)- and -S(-O)2-; Z represents a group of formula -(CR13R14)q-; R1 is selected from the group, consisting of C1-C12alkyl, optionally substituted with one substituent, selected from naphthyl, indole and biphenyl; C2-C12alkenyl, substituted with a substituent, selected from thienyl, naphthyl and phenyl, with the said phenyl being optionally substituted with 1-2 substituents; selected from halogen, trifluoroalkyl, C1-C6alkyl, methoxy and hydroxy; C3-C6cycloalkyl; C6-C10aryl, optionally substituted with 1-2 substituents, selected from halogen, phenyl, amino, phenoxy, C1-C6alkyl, methoxy, hydroxyl and carboxy; and C4-C9heteroaryl, selected from indole, quinoline, quinoxaline, benzofuranyl, benzothiophene, benzimidazole, benzotriazole, benzodioxin, benzothiasole, pyrazole, furyl and isoxazole, optionally substituted with a substituent, selected from C1-C6alkyl and phenyl; R2 and R3 each is independently selected from the group, consisting of H and C1-C12alkyl; R4a is selected from the group, consisting of H, C1-C12alkyl, optionally substituted with phenyl; C2-C12alkenyl, C3-C6cycloalkyl, C6aryl, C(=O)R15, C(=O)NR15R16, C(=O)OR15, SO2R15 and -C(=NR15)-NR16R17; R4d represents hydrogen or R4a and R4b, taken together with a nitrogen atom, which they are bound to, form an optionally substituted heterocyclic fragment, selected from piperidine, morpholine, pyrrolidine and azetidine, where the substituent is selected from C1-C12alkyl, hydroxy, halogen, carboxy and oxo; each R5a and R5b represents H, or R6, R7 and R8 each is independently selected from the group, consisting of H, C1-C12alkyl, C3-C6cycloalkyl, C6-C10aryl, optionally substituted with halogen, or taken together with a carbon atom, which they are bound to, two or more of R6, R7 and R8 form a fragment, selected from the group, consisting of C2-C12alkenyl; C3-C6cycloalkyl, optionally substituted with C1-C6alkyl; C6aryl, optionally substituted with 2 substituents, selected from halogen; each R9 and R10 represents H or C1-C12alkyl, substituted with naphthyl; each R11 and R12 represents H; R13 and R14 represent H, or each R15, R16 and R17 is independently selected from the group, consisting of H, C1-C12alkyl, C3-C6cycloalkyl, C6aryl, substituted with one substituent, selected from C1-C6alkyl; and C5-heteroaryl, additionally containing one nitrogen atom, with the said heteroaryl representing pyridyl; q represents an integer number, selected from the group, consisting of 2, 3 and 4; r represents 1; or its pharmaceutically acceptable salt. The invention also relates to particular compounds of 1,4-diazepan-2-one derivatives.

EFFECT: obtaining 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists.

21 cl, 7 tbl, 110 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to dermatology, and can be used for selecting a therapeutic approach to acne in females by examining biological fluids and prescribing preparations depending on the clinical findings. The biological fluids are blood and urine; blood serum hormones and steroid urine profile are tested, and the derived values are compared to the standard norms specific for the absence of acne, while the preparations are prescribed according to the comparison results. Specifically, if observing an increase of blood luteinising hormone up to 16 mIU/ml, testosterone up to 4 ng/ml, an increase of urine androsterone up to 20 mcmole/24 hours, etiocholanolone up to 11 mcmole/24 hours, total 17-ketosteroids up to 35 mcmole/24 hours, van de Calseyde's discriminant up to 3, the combined oral contraceptive Jess with the anti-androgenic effect. If also observing an increase of immunoreactive protein up to 12.90 mcUnit/ml and insulin-line growth factor 1 up to 361.04 ng/ml, the combined oral contraceptive Jess and Metformine or Metformine are prescribed. If observing a decrease of blood oestradiol up to 140 pmole/l or an increase of the concentration of luteinising hormone up to 7 mIU/ml, dihydroepiandrosterone sulphate up to 4 mmole/l, 17 - hydroxyprogesterone up to 4 nmole/l and testosterone up to 4 nmole/l in blood and an increase of urine androsterone up to 17 mcmole/24 hours, etiocholanolone up to 17 mcmole/24 hours, 11 - ketoandrosterone up to 2.5 mcmole/24 hours, 11 - ketoetiocholanolone up to 2.5 mcmole/24 hours, 17 - ketosteroids up to 50 mcmole/24 hours and van de Calseyde's discriminant up to 3, the glucocorticoid Metypred is prescribed. The high blood concentration of luteinising hormone up to 15 mIU/ml, dihydroepiandrosterone sulphate up to 6.82 mcmole/l, 17 - hydroxyprogesterone up to 4 nmole/l and an increase of urine androsterone up to 19.5 mcmole/24 hours, etiocholanolone up to 16 mcmole/24 hours, dihydroepiandrosterone up to 7 mcmole/24 hours, 17 - ketosteroids up to 45 mcmole/24 hours and van de Calseyde's discriminant up to 3.5 enables using the combined oral contraceptive Jess and the glucocorticoid Metypred. And the preparation Dostinex is prescribed in observing the above values in a combination with an increase of blood prolactin up to 750 IU/ml and a decrease of blood oestradiol up to 95.48 pcg/ml.

EFFECT: method enables providing higher therapeutic selectivity and clinical effectiveness in acne without the need of thorough examination to be conducted.

4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutics, in particular represents composition for topic application, which includes, into physiologically acceptable medium at least one derivative of naphthoic acid, benzoylperoxide and at least one film-forming component.

EFFECT: invention is characterised by the fact that said compound of naphthoic acid and benzoylperoxide are in dispersed in said composition form.

23 cl, 14 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to an herbal formulation of topical nanoemulsion for treating acne-related skin disorders. The above formulation contains an aqueous phase comprising a therapeutic agent, rose water and/or lemon juice, and an oil phase containing an essential oil, a non-ionic surfactant and an accessory surfactant. The aqueous and oil phases are related within the range of 1:1 to 1:2, while a particle size of the herbal formulation is less than 5 nm. The essential oil is presented by tea tree oil, basil oil, rosemary oil, lavender oil, jojoba oil, bergamot oil, clove oil and peppermint oil. The invention also refers to a method for preparing the herbal formulation which involves providing the aqueous and oil phases, mixing the above phases to produce a mixture to be emulsified with the non-ionic surfactant to prepare a macroemulsion. The prepared macroemulsion is mixed with ethanol to produce a nanoemulsion with a particle size less than 5 nm.

EFFECT: invention provides the herbal formulation with good penetration, prolonged effect causing no irritation.

8 cl, 4 dwg, 7 ex

FIELD: chemistry.

SUBSTANCE: invention relates to cosmetic industry and provides a composition for depositing on keratin surfaces, which contains composition particles in the form of fused agglomerates having a part containing at least one dye and a part containing at least one transparent and translucent thermoplastic material, where the composition particles contain, based on the weight of all of the powdered composition material, about 10 to 90 parts of the dye part and about 90 to 10 parts of the transparent and translucent thermoplastic material part, and a method of producing the powdered composition material.

EFFECT: invention enables to obtain cosmetic compositions which will have an improved outer appearance on the skin and fewer SKU.

23 cl, 10 tbl, 11 ex

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine and is intended for oral cavity care. Compositions contain: a) guanidine-based active substance, b) film-forming polymer, c) hydrophobic modifier of viscosity in quantity, sufficient for provision of composition for oral cavity care with time particle sedimentation more than 20 minutes, and d) oil carrier. Guanidine-based active substance preferably represents L-arginine. Film-forming polymer preferably represented GANTREZ. Hydrophobic modifier of viscosity preferably represents thickened mineral oil. Oil carrier preferably represents natural oil. Composition is enclosed in gelatine capsule. Method of teeth cleaning includes application on teeth of composition for oral cavity care in such a way that composition for oral cavity care cleans teeth. Device for oral cavity care, which contains: handle, fastened on handle head, where head has external surface and a row of teeth-cleaning elements, projecting outwards on external surface, and gelatine capsule, which contains composition for oral cavity care, located on head.

EFFECT: group of inventions makes it possible to increase teeth cleaning efficiency.

14 cl, 2 ex, 1 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to the encapsulation of active ingredients and to processing textile materials. Claimed are: a method of processing textile materials, containing microcapsules of active ingredients, fibres and/or textile materials, obtained from the said method, and their cosmetic or pharmaceutical application and/or their application as a repellent.

EFFECT: claimed invention makes it possible to increase the active ingredient stability for an acceptable number of washings.

16 cl, 6 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to application of composition, which contains Polygonum aviculare grass 20-25 wt %, cowberry leaves 13-17 wt %, Viburnum sargentii koehne fruits 5-9 wt %, fruits of dog-rose of different of Far-East species 20-25 wt %, Schisandra chinensis seeds 13-17 wt %, Fragaria orientalis leaves 5-9 wt % and corn stigmas 5-9 wt %, as means with oil protective activity in treatment of glomerulonephritis.

EFFECT: invention provides positive influence on basic indices of glomerulonephritis: promotes recovery of diuresis, reduction of proteinuria, reduction of azotemia, cryoglobulinemia and level of circulating immune complexes.

2 tbl

FIELD: medicine.

SUBSTANCE: integrated therapy additionally involves administering thin-walled Capsicum annuum powder of the type paprika in a dose of 30 g with the specified selenium contents of 1 mg/kg and a capsule of alpha-tocopherol acetate in a dose of 100 mg manufactured by Lyumi, LLC (Ekaterinburg) orally during meals 3 times a day. The length of the treatment is 20 days.

EFFECT: invention enables reducing the time of the treatment, increasing its efficacy, and prolonging remission.

1 tbl, 2 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine. Described is a wet product from a non-woven material, soaked with a substance for personal hygiene, which is applied in household or for local processing for medicinal purposes. The non-woven material represents a bonded fibrous cloth, possessing hydrophilic properties, or a fibrous cloth, to which hydrophilic properties have been applied by processing with moisturising additives.

EFFECT: wet product possesses the high absorbing property and increased ability of releasing a substance, possessing the absorbing ability, and its transfer onto the surface.

21 cl, 3 tbl

FIELD: medicine.

SUBSTANCE: invention refers to dentistry, namely represents an encapsulated oral care composition and an oral care device. According to the invention, the composition contains: (a) a gelatine capsule; and (b) an oral care composition inside the capsule and containing: (i) a hydrophilic active ingredient, (ii) a hydrophobic structuring ingredient, and (iii) an oil carrier. The hydrophilic active ingredient preferentially represents cetylpyridinium chloride. The hydrophobic structuring ingredient preferentially represents gelated mineral oil.

EFFECT: developing the composition according to the invention solves the problem of cetylpyridinium chloride migration and fish-eye capsule defect.

9 cl, 1 ex, 1 tbl

FIELD: chemistry.

SUBSTANCE: claimed invention relates to cosmetic field, namely represents method of colouring or lightening of keratin fibres, which includes stage of mixing without preparation at the moment of application of two compositions (A) and (B) and application of said mixture on said fibres; with said mixture including, at least, 25% of fatty substances relative to the total weight of composition, obtained in mixing two compositions (A)+(B).

EFFECT: method by invention makes it possible to produce intensive and uniform colouring of keratin fibres, with method simultaneously being easy to realise, because mixture in form of oil-reach emulsion does not flow down, but remains on application place, as well as makes it possible to lighten keratin fibres.

19 cl, 3 tbl, 1 ex

Shower gel // 2555358

FIELD: cosmetology.

SUBSTANCE: shower gel comprises lauryl glucoside, sodium carboxylate and lauryl glucoside, coco glucoside, cocon amidopropylbetaine, guar-hydroxypropyltrionium chloride, coco glucoside and glyceryl oleate, ethyl alcohol, a fragrance component, sanguinitrine derived from small-fruited plumepoppy, citric acid and water. The components of the gel are in a certain ratio in wt %.

EFFECT: invention provides high washing and foam-generating capacity with soft action which does not disturb the lipid layer of the skin and has a disinfecting action, without destroying own microflora of human skin.

3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to liposomal compositions for application in cosmetic industry, including i) from 0.001 to 1 wt % of cyclo-(Arg-Gly-Asp-DPhe-Acha) and/or its salt or solvate, ii) from 0.01 to 20 wt % of one or more lipids; iii) from 60 to 99.99 wt % of one or more physiologically acceptable solvents, as well as to method of their obtaining and application for care and preservation of general condition of skin or hare, for prevention or reduction of wrinkles.

EFFECT: claimed compositions demonstrate favourable properties: improved effectiveness, higher stability, reduced immunogenic reactions in comparison with known properties.

18 cl, 3 dwg, 29 tbl, 18 ex

FIELD: medicine, oncology, amino acids.

SUBSTANCE: invention relates, in particular, to the development of an antitumor preparation based on natural substances. Invention relates to an amino acid preparation comprising at least one modified essential amino acid obtained by treatment of amino acid by ultraviolet radiation (UV) at wavelength 250-350 nm for 12-80 h at temperature 15-30oC or with ozone at temperature 15-25oC. The modified amino acid has no toxicity for health cells. Also, invention relates to a method for preparing such preparation. Invention provides the development of an antitumor preparation based on modified amino acids and expanded assortment of antitumor preparations being without cytotoxicity for normal cells.

EFFECT: valuable medicinal antitumor properties of preparation.

8 cl, 4 tbl, 2 dwg, 4 ex

Up!